{"preliminary_commentary":{"by_channel":{"x_thread":20,"podcast":7,"youtube":4,"x_video":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03022825\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-10-31T04:12:15.302Z","note":"Automated from the 21 newest of 34 indexed sources (Jul 2019 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.","passages_read":21,"text":"- Whether treatment provides benefit beyond the natural history of disease\n- Whether papillary-only efficacy can be inferred from data including CIS\n- Whether outcomes can be compared reliably across bladder cancer treatments\n\nAlso discussed: bladder preservation, IL-15 immune activation, treatment tolerability."},"drugs_tested":[["nogapendekin alfa inbakicept (N-803)","BCG"]],"indication":"BCG-unresponsive high-grade non-muscle invasive bladder cancer","name":"QUILT-3.032","nct_id":"NCT03022825","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=quilt-3-032-nct03022825. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"BCG+N-803","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2029-03-01","type":"ESTIMATED"},"conditions":["Bladder Cancer"],"enrollment":{"count":190,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"N-803 and BCG","otherNames":[],"type":"DRUG"},{"name":"N-803","otherNames":[],"type":"DRUG"}],"last_update":"2025-10-16","lead_sponsor":"ImmunityBio, Inc.","official_title":"QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2024-10-01","type":"ACTUAL"},"primary_outcomes":[{"measure":"Complete Response","timeFrame":"60 Months"},{"measure":"Disease-Free Rate","timeFrame":"12 Months"}],"references":[{"citation":"Chang SS, Chamie K, Kramolowsky E, Gonzalgo ML, Agarwal PK, Bassett JC, Bjurlin M, Cher ML, Clark W, Cowan BE, David R, Goldfischer E, Guru K, Jalkut MW, Kaffenberger SD, Kaminetsky J, Corcoran A, Koo AS, Sexton WJ, Tikhonenkov SN, Shah MS, Trabulsi EJ, Trainer AF, Spilman P, Huang M, Bhar P, Drusbosky LM, Sender L, Brown B, Reddy S, Soon-Shiong P. Prolonged Progression-Free Survival, Disease-Free Survival, and Cystectomy Avoidance With IL-15 Receptor Lymphocyte-Stimulating Agent NAI Plus Bacillus Calmette-Guerin in Bacillus Calmette-Guerin-Unresponsive Papillary-Only Nonmuscle-Invasive Bladder Cancer. J Urol. 2026 Jan;215(1):44-56. doi: 10.1097/JU.0000000000004782. Epub 2025 Sep 16.","pmid":"40956664","type":"DERIVED"},{"citation":"Chamie K, Chang SS, Rosser CJ, Kramolowski E, Gonzalgo ML, Sexton WJ, Spilman P, Sender L, Reddy S, Soon-Shiong P. N-803 Plus BCG Treatment for BCG-Naive or -Unresponsive Non-Muscle Invasive Bladder Cancer: A Plain Language Review. Future Oncol. 2024;20(31):2307-2317. doi: 10.1080/14796694.2024.2363744. Epub 2024 Jul 2.","pmid":"38953850","type":"DERIVED"}],"start_date":{"date":"2017-06-02","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer","url":"https://clinicaltrials.gov/study/NCT03022825"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/quilt-3-032-nct03022825"}